Intelligence Layer

News

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

Hub signal

Search-friendly coverage

Keep the current route structure, but present it with the same premium hierarchy as the homepage.

Explore

Search-friendly hub pages

Regulators

Regulatory Updates

FDA, EMA, PMDA, MHRA, and global regulatory coverage in one crawlable hub.

Trials

Clinical Trial Watch

Phase readouts, trial design updates, enrollment milestones, and study results.

Pipeline

Drug Pipeline

Regulatory pipeline signals, approvals, and market-moving development updates.

Live pharma index

Full coverage

Every signal, indexed and searchable

Browse the complete catalog across approvals, trials, research, devices, and deals - refreshed twice a day.

350+

trusted sources

8k+

indexed stories

2x

daily refresh

Coverage

Latest indexed stories

9,122 stories indexed, page 104 of 153

🇺🇸Mar 28, 2019CROflorencehc.com

Featured signal

ALCOA-C in Clinical Trial Electronic Document Management

Publisher

Florence Healthcare

Limited excerpt on-platform. Click anywhere on this card to open the original publisher in a new tab.

Florence HealthcareOriginal publisher link

Canonical metadata stays public, while full text remains on the original site.

🇺🇸Mar 19, 2019Researchcidrap.umn.edu

Stewardship / Resistance Scan for Mar 18, 2019

CIDRAPOriginal source

🌍Mar 14, 2019Industryemzorpharma.com

Emzor’s Position on the BBC Documentary on Codeine

Emzor PharmaceuticalOriginal source

🇺🇸Mar 14, 2019Researchcidrap.umn.edu

Antibiotics before miscarriage surgery not tied to fewer infections

CIDRAPOriginal source

🌍Feb 27, 2019Industryir.cyclerion.com

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

Cyclerion TherapeuticsOriginal source

🇺🇸Feb 13, 2019CROflorencehc.com

5 Key Advantages of eRegulatory

Florence HealthcareOriginal source

🇺🇸Jan 30, 2019CROflorencehc.com

Observations from TMF Summit 2019: The Post-eTMF World

Florence HealthcareOriginal source

🌍Jan 29, 2019Industryir.cyclerion.com

Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

Cyclerion TherapeuticsOriginal source

🇺🇸Jan 19, 2019CROflorencehc.com

How Lauren Begnaud Transitioned 65 Sites to eRegulatory at US Oncology

Florence HealthcareOriginal source

🇺🇸Dec 29, 2018CROflorencehc.com

Thank you for a great 2018!

Florence HealthcareOriginal source

🇺🇸Dec 20, 2018CROflorencehc.com

Key Expectations of Clinical Trial Operations Leaders in 2019

Florence HealthcareOriginal source

🇺🇸Oct 25, 2018CROflorencehc.com

Four Observations from Site Solutions Summit

Florence HealthcareOriginal source

🇺🇸Sep 13, 2018CROflorencehc.com

Ten Ways Florence eBinders™ Accelerates Study Startup

Florence HealthcareOriginal source

🇺🇸Sep 11, 2018CROflorencehc.com

Florence Named to Top 100 Places to Work in Atlanta

Florence HealthcareOriginal source

🇩🇰Sep 3, 2018Industryserviersymphogen.com

Symphogen elects new Board members to support the Company’s long-term development

SymphogenOriginal source

🇺🇸Aug 18, 2018CROflorencehc.com

4 Strategies for ICH GCP E6(R2) Compliance

Florence HealthcareOriginal source

🇺🇸Aug 13, 2018CROflorencehc.com

Guide | FDA Inspections of Trial Sites with Electronic Systems

Florence HealthcareOriginal source

🇺🇸Aug 7, 2018CROflorencehc.com

Ten Must-Have Capabilities When Evaluating eRegulatory Platforms

Florence HealthcareOriginal source

🇬🇧Jun 26, 2018Researchhdruk.ac.uk

Rhos Walker becomes Chief Strategy Officer at HDR UK

Health Data Research UKOriginal source

🇩🇰May 30, 2018Industryserviersymphogen.com

Symphogen further strengthens its immuno-oncology pipeline by advancing into two additional clinical trials

SymphogenOriginal source

🇺🇸Mar 20, 2018Researchcidrap.umn.edu

Study: Non-antibiotic drugs affect gut bacteria, could promote resistance

CIDRAPOriginal source

🌍Jan 21, 2018Industrydeltapharma.com

Ferias internacionales 2025

Delta PharmaOriginal source

🇩🇰Nov 30, 2017Industryserviersymphogen.com

Symphogen receives milestone payment for initiation of Phase 1b trial in infectious disease

SymphogenOriginal source

🇩🇰Sep 11, 2017Industryserviersymphogen.com

Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress

SymphogenOriginal source

🇩🇰Aug 31, 2017Industryserviersymphogen.com

Symphogen presents Sym004 Phase 2 data at ESMO 2017 Congress

SymphogenOriginal source

🌍Jul 18, 2017Industrydeltapharma.com

¡UNA NUEVA UBICACIÓN!

Delta PharmaOriginal source

🌍Jul 16, 2017Industryimmutep.com

Prima BioMed Announces Second Milestone Payment for IMP701 Program - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jul 9, 2017Industryimmutep.com

Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jun 29, 2017Industryimmutep.com

Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jun 26, 2017Industryimmutep.com

Operational Update - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jun 6, 2017Industryimmutep.com

ASCO Poster 2017 - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jun 4, 2017Industryimmutep.com

LAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍May 31, 2017Industryimmutep.com

Prima BioMed Announces Formation of Clinical Advisory Board - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍May 17, 2017Industryimmutep.com

Data from Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Apr 18, 2017Industryimmutep.com

Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Apr 12, 2017Industryimmutep.com

Prima BioMed receives A$492,144 Tax Refund from Australian Government - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Apr 4, 2017Regulatoryaifd.org.tr

Yenilikçi İlaçlar

AIFD TurkeyOriginal source

🌍Apr 4, 2017Regulatoryaifd.org.tr

Doktorunuzla Görüşme Öncesi ve Sonrası Hazırlıklarınızı Yapmayı Unutmayın!

AIFD TurkeyOriginal source

🌍Apr 4, 2017Regulatoryaifd.org.tr

Akılcı İlaç Kullanımı

AIFD TurkeyOriginal source

🌍Mar 16, 2017Industryimmutep.com

Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Mar 2, 2017Regulatoryaifd.org.tr

Kullanım Talimatını Tanıyalım

AIFD TurkeyOriginal source

🌍Mar 2, 2017Industryimmutep.com

USA Patent Grants for IMP321 in Cancer - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Mar 1, 2017Regulatoryaifd.org.tr

Hasta Hakları ve Sorumlulukları

AIFD TurkeyOriginal source

🌍Feb 25, 2017Industryimmutep.com

First Half 2017 Operational Update - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Feb 14, 2017Industryimmutep.com

Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jan 24, 2017Industryimmutep.com

Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jan 21, 2017Industryimmutep.com

Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jan 19, 2017Industryimmutep.com

Prima BioMed to Maintain NASDAQ Listing - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jan 13, 2017Industryimmutep.com

Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jan 6, 2017Industryimmutep.com

Prima BioMed enters new Material Transfer Agreement with Cytlimic - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jan 3, 2017Industryimmutep.com

Prima announces new Product Candidate IMP761 – a LAG-3 Agonist Antibody - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🇩🇰Sep 15, 2016Industryserviersymphogen.com

Symphogen Names New Chief Financial Officer

SymphogenOriginal source

🇩🇰Aug 18, 2016Industryserviersymphogen.com

Symphogen’s founding CEO Kirsten Drejer steps down and becomes Executive Director

SymphogenOriginal source

🌍Dec 10, 2013Industryscripps.org

How Much Screen Time Is Too Much for Kids?

Scripps HealthOriginal source

🌍Nov 2, 2013Industryscripps.org

When Is It Safe to Travel with a Newborn?

Scripps HealthOriginal source

🇧🇪Sep 12, 2011Regulatoryfamhp.be

« Un médicament n’est pas un bonbon ! »

FAMHP (Belgium)Original source

🇧🇪Oct 12, 2010Regulatoryfamhp.be

"Miracle Mineral Solution" or "MMS": warning

FAMHP (Belgium)Original source

🇧🇪Jan 1, 2009Regulatoryfamhp.be

@ctua 1/4 2009

FAMHP (Belgium)Original source

🇧🇪Jan 1, 2008Regulatoryfamhp.be

@ctua 1/4_2008

FAMHP (Belgium)Original source

🌍Jun 1, 1778Industrydeltapharma.com

Nimesulida: asegura tu suministro

Delta PharmaOriginal source